DOP2016000250A - Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa - Google Patents

Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa

Info

Publication number
DOP2016000250A
DOP2016000250A DO2016000250A DO2016000250A DOP2016000250A DO P2016000250 A DOP2016000250 A DO P2016000250A DO 2016000250 A DO2016000250 A DO 2016000250A DO 2016000250 A DO2016000250 A DO 2016000250A DO P2016000250 A DOP2016000250 A DO P2016000250A
Authority
DO
Dominican Republic
Prior art keywords
hemitartrate
formula
crystalline forms
methods
glucosilceramide
Prior art date
Application number
DO2016000250A
Other languages
English (en)
Inventor
Diane P Copeland
Abizer Harianawala
Jeffrey Skell
John Marshall
Gerard Palace
Hanlan Liu
Chris Willis
Renu Bhardwaj
Jianmei Kochling
Craig Siegel
Seng Cheng
Judith Peter-Schmitt
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43431870&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2016000250(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of DOP2016000250A publication Critical patent/DOP2016000250A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente solicitud proporciona formas cristalinas únicas y nuevas composiciones farmacéuticas de Hemitartrato de Fórmula (I) que comprenden las formas cristalinas de Hemitartrato de Fórmula (I) descritas en la presente, al igual que métodos para inhibir glucosilceramida sintasa o reducir las concentraciones de glicoesfingolípidos en un sujeto que lo necesita. Adicionalmente, proporciona métodos para preparar formas cristalinas especificas de Hemitartrato de Fórmula (I). Así como también proporciona formulaciones farmacéuticas estables de Hemitartrato de Fórmula (I), terapias de combinación con el compuesto de Fórmula (I) o ventas aceptables para uso farmacéutico del mismo (incluyendo Hemitartrato de Fórmula (I)) y métodos de tratamiento con el compuesto de Fórmula (I) o sales aceptables para uso farmacéutico del mismo (incluyendo Hemitartrato de Fórmula (I)) que minimiza el riesgo de interacciones fármaco/fármaco.
DO2016000250A 2009-11-27 2016-09-19 Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa DOP2016000250A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26474809P 2009-11-27 2009-11-27

Publications (1)

Publication Number Publication Date
DOP2016000250A true DOP2016000250A (es) 2017-02-15

Family

ID=43431870

Family Applications (2)

Application Number Title Priority Date Filing Date
DO2012000141A DOP2012000141A (es) 2009-11-27 2012-05-23 Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa
DO2016000250A DOP2016000250A (es) 2009-11-27 2016-09-19 Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DO2012000141A DOP2012000141A (es) 2009-11-27 2012-05-23 Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa

Country Status (41)

Country Link
US (6) US11458119B2 (es)
EP (5) EP3133070B1 (es)
JP (6) JP2013512252A (es)
KR (5) KR102073207B1 (es)
CN (5) CN112521367B (es)
AR (3) AR079152A1 (es)
AU (3) AU2010324810B2 (es)
BR (1) BR112012012947B8 (es)
CA (3) CA2781676C (es)
CL (2) CL2012001348A1 (es)
CR (1) CR20120277A (es)
CY (3) CY1115880T1 (es)
DK (3) DK2504332T4 (es)
DO (2) DOP2012000141A (es)
EA (3) EA023923B1 (es)
EC (2) ECSP12011926A (es)
ES (4) ES2586947T3 (es)
GT (1) GT201200161A (es)
HK (2) HK1203485A1 (es)
HR (3) HRP20140780T4 (es)
HU (2) HUE029371T2 (es)
IL (4) IL310635A (es)
LT (2) LT2796457T (es)
MA (1) MA33838B1 (es)
ME (1) ME02477B (es)
MX (1) MX358345B (es)
MY (2) MY192644A (es)
NI (1) NI201200096A (es)
NZ (3) NZ715108A (es)
PE (2) PE20171255A1 (es)
PH (1) PH12015502514A1 (es)
PL (4) PL3133070T3 (es)
PT (4) PT3599237T (es)
RS (3) RS53503B2 (es)
SG (2) SG10201800136QA (es)
SI (3) SI3133070T1 (es)
SM (1) SMT201600273B (es)
TN (1) TN2012000237A1 (es)
TW (3) TWI586663B (es)
UA (1) UA113491C2 (es)
WO (1) WO2011066352A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
HUE029371T2 (en) 2009-11-27 2017-02-28 Genzyme Corp GENZ 112638 For treatment of Gaucher or Fabry disease in combination therapy
JP6175431B2 (ja) * 2011-06-20 2017-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ ムコ多糖症およびその他のリソソーム障害に対する抗ｔｎｆ療法
WO2013036875A1 (en) 2011-09-07 2013-03-14 Mount Sinai School Of Medicine Ceramidase and cell differentiation
WO2013078413A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of lipid storage
ES2897825T3 (es) 2012-06-01 2022-03-02 Icahn School Med Mount Sinai Niveles de ceramida en el tratamiento y prevención de infecciones
ES2739811T3 (es) 2013-03-14 2020-02-04 Icahn School Med Mount Sinai Composiciones terapéuticas de ceramidasa ácida y métodos de fabricación y uso de ellas
US10227323B2 (en) * 2013-09-20 2019-03-12 Biomarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
US20170129869A1 (en) * 2014-07-03 2017-05-11 Dr. Reddy's Laboratories Limited Amorphous form of eliglustat hemitartarate
WO2016166170A1 (en) 2015-04-14 2016-10-20 Sandoz Ag Crystalline eliglustat hydrochloride
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
US11116755B2 (en) 2015-11-18 2021-09-14 Genzyme Corporation Biomarker of polycystic kidney disease and uses thereof
CN107445938B (zh) * 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
CN106349210A (zh) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
WO2018193090A2 (en) * 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
WO2018225085A1 (en) 2017-06-05 2018-12-13 Cipla Limited Stable solid dispersions of eliglustat hemitartrate
CN110799191B (zh) 2017-06-16 2023-05-26 贝塔制药有限公司 N-(2-(2-(二甲氨基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)氨基)苯基)丙烯酰胺及其盐的药物制剂
US20200222310A1 (en) * 2017-08-08 2020-07-16 Kashiv Biosciences, Llc Pharmaceutical composition comprising eliglustat
US20200197366A1 (en) * 2017-08-08 2020-06-25 Kashiv Biosciences, Llc Pharmaceutical composition comprising eliglustat
AU2018386182B2 (en) 2017-12-15 2024-03-28 Genzyme Corporation Methods for treating Gaucher disease
WO2019123476A1 (en) * 2017-12-20 2019-06-27 Sarudbhava Formulations Private Limited Stable amorphous eliglustat premix and process for the preparation thereof
WO2019211778A2 (en) * 2018-05-02 2019-11-07 Kashiv Biosciences, Llc Pro-drugs of eliglustat
US20210113703A1 (en) * 2018-05-27 2021-04-22 Bioasis Technologies Inc. Treatment of gaucher disease
CN110878079A (zh) * 2018-12-31 2020-03-13 北京启慧生物医药有限公司 一种高纯度依利格鲁司他的制备方法
CN116120274A (zh) * 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (de) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh Neue aromatische verbindungen, ihre herstellung und verwendung
US5041441A (en) 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
US5302609A (en) 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
HUT73527A (en) 1993-08-13 1996-08-28 Seikagaku Kogyo Co Ltd Remedy for nervous diseases
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
EP0742789B1 (en) 1994-02-02 2000-08-30 The Liposome Company, Inc. Pharmaceutically active compounds and liposomes, and methods of use therof
JP3850437B2 (ja) 1994-06-10 2006-11-29 生化学工業株式会社 ２−アシルアミノプロパノール化合物及び医薬組成物
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20030073680A1 (en) 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6890949B1 (en) 1999-07-09 2005-05-10 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO1997010817A1 (en) 1995-09-20 1997-03-27 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP3993908B2 (ja) 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
CA2336549A1 (en) 1998-07-27 2000-02-10 Johns Hopkins University Methods for treating conditions modulated by lactosylceramide
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
JP2003521479A (ja) * 1999-07-09 2003-07-15 リージェンツ オブ ザ ユニバーシティ オブ ミシガン アミノセラミド様化合物および治療目的での使用方法
CA2396079A1 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US20040252299A9 (en) 2000-01-07 2004-12-16 Lemmo Anthony V. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
ATE308324T1 (de) 2000-04-24 2005-11-15 Teva Pharma Zolpidem hemitartrat
US6436987B1 (en) 2000-06-08 2002-08-20 Pfizer Inc. Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid
US7148251B2 (en) 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP2004531478A (ja) 2001-01-10 2004-10-14 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン アミノセラミド様化合物および治療目的での使用方法
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20020198240A1 (en) 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
CA2435037A1 (en) * 2001-01-18 2002-07-25 Silke Schumacher Bifunctional fusion proteins with glucocerebrosidase activity
EP1409467B1 (en) 2001-07-16 2012-04-18 Genzyme Corporation A n-acylsphingosine glucosyltransferase inhibitor
EP1281755A3 (en) 2001-07-31 2003-06-18 Pfizer Products Inc. Variants of the human cyp2d6 gene
PE20030329A1 (es) 2001-08-08 2003-05-12 Takeda Chemical Industries Ltd Compuesto biciclico con actividad antagonista de ccr5 y produccion del mismo
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
WO2004004702A2 (en) 2002-07-09 2004-01-15 The Scripps Research Institute Method to inhibit ischemia and reperfusion injury
US20050032070A1 (en) 2003-08-05 2005-02-10 Sebastian Raimundo Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications
DE602005027308D1 (de) * 2004-01-27 2011-05-19 Synthon Bv Stabile salze von olanzapin
CA3113166A1 (en) 2004-09-30 2006-04-13 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
CN101039921A (zh) 2004-10-13 2007-09-19 法玛西雅厄普约翰有限责任公司 3－[5－氯－4－[(2,4－二氟苄基)氧基]－6－氧代嘧啶－1(6h)－基]－n－(2－羟乙基)－4－甲基苯甲酰胺的晶形
JP2008519840A (ja) * 2004-11-10 2008-06-12 ジェンザイム・コーポレイション 糖尿病の処置方法
WO2007038676A2 (en) * 2005-09-28 2007-04-05 Teva Pharmaceutical Industries Ltd. Polymorphic forms of ladostigil tartrate
AU2006297475A1 (en) * 2005-10-03 2007-04-12 Mallinckrodt Inc. Process for preparing zolpidem hemitartrate and tartrate polymorphs
MX2007016179A (es) 2006-04-17 2008-03-11 Teva Pharma Formas cristalinas de o-desmetilvenlafaxina.
PT2032134E (pt) * 2006-05-09 2015-10-07 Genzyme Corp Métodos de tratamento da doença do fígado gorduroso
KR101271225B1 (ko) 2006-10-31 2013-06-03 삼성디스플레이 주식회사 발광 다이오드 칩 및 발광 다이오드 광원 모듈의 제조 방법
TWI314226B (en) 2006-12-07 2009-09-01 Ind Tech Res Inst Piezoelectricity-driving optical lens module
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
MX2009010557A (es) 2007-03-30 2009-11-19 Amicus Therapeutics Inc Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
CA2685332A1 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2167485B1 (en) * 2007-05-31 2015-09-30 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
DE102007029581B4 (de) 2007-06-26 2020-04-09 GM Global Technology Operations LLC (n. d. Ges. d. Staates Delaware) Kraftfahrzeugdach und Kraftfahrzeugkarosserie
US20090299645A1 (en) 2008-03-19 2009-12-03 Brandon Colby Genetic analysis
WO2009117150A2 (en) * 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
RS59908B1 (sr) 2009-11-27 2020-03-31 Adverio Pharma Gmbh Postupak za proizvodnju metil-{4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilkarbamata
CN102753161A (zh) 2009-11-27 2012-10-24 贝林格尔.英格海姆国际有限公司 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗
HUE029371T2 (en) 2009-11-27 2017-02-28 Genzyme Corp GENZ 112638 For treatment of Gaucher or Fabry disease in combination therapy
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
KR20140033432A (ko) 2011-06-21 2014-03-18 노파르티스 아게 (s)-피롤리딘-1,2-디카르복실산 2-아미드 1-(｛4-메틸-5-[2-(2,2,2-트리플루오로-1,1-디메틸-에틸)-피리딘-4-일]-티아졸-2-일｝-아미드)의 다형체
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
JP6728842B2 (ja) 2016-03-24 2020-07-22 オムロン株式会社 光学計測装置
CN107445938B (zh) 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof

Also Published As

Publication number Publication date
EP2504332A1 (en) 2012-10-03
EA201890254A3 (ru) 2019-02-28
EP3896069A1 (en) 2021-10-20
TWI606827B (zh) 2017-12-01
US20210393590A1 (en) 2021-12-23
ES2875382T3 (es) 2021-11-10
LT2796457T (lt) 2016-09-12
PL2504332T5 (pl) 2021-08-23
TN2012000237A1 (en) 2013-12-12
GT201200161A (es) 2014-01-27
US20230172903A1 (en) 2023-06-08
US20210369672A1 (en) 2021-12-02
PL2796457T3 (pl) 2017-04-28
EP2504332B2 (en) 2021-03-17
IL310635A (en) 2024-04-01
HRP20191647T1 (hr) 2019-12-13
CR20120277A (es) 2012-09-05
SI2796457T1 (sl) 2016-10-28
UA113491C2 (xx) 2017-02-10
ES2586947T3 (es) 2016-10-19
KR20220162824A (ko) 2022-12-08
CA3140959A1 (en) 2011-06-03
RS53503B1 (en) 2015-02-27
PL2504332T3 (pl) 2014-10-31
CN105777707B (zh) 2020-10-13
EP3133070A1 (en) 2017-02-22
AR121612A2 (es) 2022-06-22
NZ625712A (en) 2016-02-26
PE20121337A1 (es) 2012-10-12
CY1115880T1 (el) 2017-01-25
EP2796457B1 (en) 2016-05-18
NZ600155A (en) 2014-10-31
JP2013512252A (ja) 2013-04-11
HK1172031A1 (en) 2013-04-12
SG10201800136QA (en) 2018-02-27
BR112012012947A2 (pt) 2017-03-01
CA2781676A1 (en) 2011-06-03
PT3599237T (pt) 2021-04-28
JP2019001809A (ja) 2019-01-10
MY160542A (en) 2017-03-15
AU2016202591B2 (en) 2017-11-30
BR112012012947B8 (pt) 2021-05-25
EA201592195A1 (ru) 2016-04-29
MX2012006083A (es) 2012-06-19
AU2017265180A1 (en) 2017-12-14
AU2010324810B2 (en) 2016-05-12
CN105753846A (zh) 2016-07-13
NI201200096A (es) 2012-10-30
KR20150125734A (ko) 2015-11-09
HUE045784T2 (hu) 2020-01-28
CL2016002589A1 (es) 2017-05-19
AU2017265180B2 (en) 2019-08-01
WO2011066352A1 (en) 2011-06-03
CA2781676C (en) 2020-05-05
HK1203485A1 (zh) 2015-10-30
CN105753846B (zh) 2019-11-15
US10888547B2 (en) 2021-01-12
KR20120115972A (ko) 2012-10-19
SG10201407881WA (en) 2015-01-29
MA33838B1 (fr) 2012-12-03
RS53503B2 (sr) 2021-07-30
AR079152A1 (es) 2011-12-28
ES2754398T3 (es) 2020-04-17
JP2023116764A (ja) 2023-08-22
ECSP12011926A (es) 2012-07-31
PE20171255A1 (es) 2017-08-28
TW201130822A (en) 2011-09-16
RS59543B1 (sr) 2019-12-31
TW201737910A (zh) 2017-11-01
JP7150528B2 (ja) 2022-10-11
IL283935A (en) 2021-07-29
PL3133070T3 (pl) 2020-01-31
PT2796457T (pt) 2016-07-14
EP3599237B1 (en) 2021-03-24
ES2493940T3 (es) 2014-09-12
CN112521367B (zh) 2024-01-02
CL2012001348A1 (es) 2012-08-24
CN112521366A (zh) 2021-03-19
JP6452635B2 (ja) 2019-01-16
EP3133070B1 (en) 2019-08-14
WO2011066352A8 (en) 2011-08-11
ECSP18063798A (es) 2020-02-28
PT3133070T (pt) 2019-11-11
EA029990B1 (ru) 2018-06-29
EA201890254A2 (ru) 2018-10-31
DK3133070T3 (da) 2019-11-11
JP6370264B2 (ja) 2018-08-08
CN102712629A (zh) 2012-10-03
CN102712629B (zh) 2016-10-12
JP2016138124A (ja) 2016-08-04
IL260299A (en) 2018-08-30
SI2504332T1 (sl) 2014-09-30
HUE029371T2 (en) 2017-02-28
HRP20161038T1 (hr) 2016-10-21
SI2504332T2 (sl) 2021-08-31
KR20200013105A (ko) 2020-02-05
EP3599237A1 (en) 2020-01-29
PT2504332E (pt) 2014-09-02
CA3075788A1 (en) 2011-06-03
CY1122698T1 (el) 2021-03-12
AU2010324810A1 (en) 2012-06-07
US20130137743A1 (en) 2013-05-30
US11458119B2 (en) 2022-10-04
EA201270646A1 (ru) 2013-01-30
AR121611A2 (es) 2022-06-22
CN105777707A (zh) 2016-07-20
BR112012012947B1 (pt) 2021-04-06
EP2796457A1 (en) 2014-10-29
DK2504332T4 (da) 2021-06-07
SMT201600273B (it) 2016-08-31
EP2504332B1 (en) 2014-06-04
JP2020189873A (ja) 2020-11-26
EA023923B1 (ru) 2016-07-29
IL219892A0 (en) 2012-07-31
KR102073207B1 (ko) 2020-02-05
MX358345B (es) 2018-08-14
CY1117996T1 (el) 2017-05-17
CA3075788C (en) 2021-12-21
HRP20140780T4 (hr) 2021-08-06
US20160166542A1 (en) 2016-06-16
AU2016202591A1 (en) 2016-05-19
DK2504332T3 (da) 2014-08-25
DOP2012000141A (es) 2012-09-30
PL3599237T3 (pl) 2021-09-27
KR20180049255A (ko) 2018-05-10
TWI586663B (zh) 2017-06-11
PH12015502514A1 (en) 2016-08-15
TWI656873B (zh) 2019-04-21
US20160120842A1 (en) 2016-05-05
SI3133070T1 (sl) 2019-11-29
TW201639562A (zh) 2016-11-16
RS54978B1 (sr) 2016-11-30
NZ715108A (en) 2017-06-30
CN112521367A (zh) 2021-03-19
ES2493940T5 (es) 2021-11-23
JP2015212291A (ja) 2015-11-26
LT3133070T (lt) 2019-11-11
DK2796457T3 (en) 2016-08-29
MY192644A (en) 2022-08-29
ME02477B (me) 2017-02-20
HRP20140780T1 (en) 2014-11-07

Similar Documents

Publication Publication Date Title
DOP2016000250A (es) Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
DOP2014000133A (es) Triazolopiridinas sustituidas
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
DOP2012000150A (es) Triazolopiridinas
CO6290656A2 (es) Derivados heterociclicos de urea y metodos de uso de los mismos -211
ECSP13013011A (es) Triazolopiridinas
ECSP099750A (es) Imidazoquinolinas con propiedades inmunomoduladoras
CL2012000248A1 (es) Compuesto conjugado de insulina; procedimiento de preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; kit farmaceutico; uso en el tratamiento de trastornos mediados por insulina.
PE20141406A1 (es) 4-(8-metoxi-1-((1-metoxipropan-2-il)-2-(tetrahidro-2h-piran-4-il)-1h-imidazo[4,5-c]quinolin-7-il)-3,5-dimetilisoxazol y su uso como inhibidor bromodominio
UY30759A1 (es) Compuestos quimicos
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CL2012000589A1 (es) Compuestos derivados de pirrolo piridin carboxamidas, inhibidores de jak2; composición farmacéutica que los comprende; uso en el tratamiento de enfermedades mieloproliferativas o cáncer, tales como policitemia vera, trombocitopenia esencial, mieloma múltiple, entre otras.
UY33078A (es) Derivados de imidazoquinolina
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
ECSP12012338A (es) Triazolopiridinas sustituidas
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
UY32731A (es) Nuevos derivados de piperidin-ilidenaminooxi-piperidin, composiciones farmacéuticas y métodos relacionados con ellos
MX2014003025A (es) Compuestos de triazolopiridina como inhibidores de fosfodiesterasa 10a.
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
UY31864A (es) Derivados de urea hetericíclica y métodos de uso de los mismos-332
UY32316A (es) Derivados de piperidina utiles en el tratamiento de infecciones bacterianas
CO6382113A2 (es) Compuestos quimicos
UY32333A (es) Derivados cuaternarios de piridina y utilización de los mismos
BR112012031289A2 (pt) novos derivados 1,4-diazepanos, inibidores de pde-5